title: The expression of podoplanin is associated with poor outcome in cutaneous squamous cell carcinoma.
abstract: BACKGROUND
  Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and can be both locally invasive and metastatic at distant sites. While research efforts have been made to predict poor outcome of CSCC, there is a lack of knowledge regarding molecular markers. Podoplanin has been associated with poor outcome in several types of cancer including CSCC, but this is controversial and only a few studies have evaluated the prognostic implications of podoplanin in the development of this tumor.
  
  
  METHODS
  We evaluated podoplanin expression in a series of 94 CSCCs, and searched for associations between podoplanin expression and histopathological characteristics and with events of poor clinical evolution of the disease.
  
  
  RESULTS
  Podoplanin expression was observed in 48.9% of the cases and the expression was considered moderate to intense in 19 of the cases. Moderate/intense podoplanin was associated with infiltrative growth pattern, desmoplasia, lymphovascular invasion, higher risk of nodal progression (NP) and short disease-free survival, specifically with a short latency to NP.
  
  
  CONCLUSIONS
  This article provides evidence supporting the implication of podoplanin expression as a marker of bad prognosis of CSCC.
authors.affiliation: Servicio de Dermatología, Hospital Universitario de Salamanca, Salamanca, Spain.|Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Cañueto
authors.affiliation: Servicio de Dermatología, Hospital Virgen de la Concha, Zamora, Spain.
authors.forename: Ester
authors.initials: E
authors.lastname: Cardeñoso-Álvarez
authors.affiliation: Servicio de Dermatología, Hospital Universitario de Salamanca, Salamanca, Spain.
authors.forename: Adriana
authors.initials: A
authors.lastname: Cosano-Quero
authors.affiliation: Servicio de Patología, Hospital Universitario de Salamanca, Salamanca, Spain.
authors.forename: Ángel
authors.initials: Á
authors.lastname: Santos-Briz
authors.affiliation: Servicio de Dermatología, Hospital Universitario de Salamanca, Salamanca, Spain.|Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain.
authors.forename: Emilia
authors.initials: E
authors.lastname: Fernández-López
authors.affiliation: Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain.|Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Centro de investigación del Cáncer (CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.
authors.forename: Jesús
authors.initials: J
authors.lastname: Pérez-Losada
authors.affiliation: Servicio de Dermatología, Hospital Universitario de Salamanca, Salamanca, Spain.|Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain.
authors.forename: Concepción
authors.initials: C
authors.lastname: Román-Curto
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis / Q000096:biosynthesis*; D011379:Prognosis; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology*; D046888:Tissue Array Analysis; D000098853:Podoplanin
chemical_list: D014408:Biomarkers, Tumor; D008562:Membrane Glycoproteins; C117468:PDPN protein, human; D000098853:Podoplanin
keywords: D2-40; cutaneous squamous cell carcinoma; podoplanin; prognosis